Entrada Therapeutics Inc
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV")-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a varie… Read more
Entrada Therapeutics Inc (TRDA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.083x
Based on the latest financial reports, Entrada Therapeutics Inc (TRDA) has a cash flow conversion efficiency ratio of -0.083x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.31 Million) by net assets ($340.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Entrada Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Entrada Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Entrada Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Entrada Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhang Jia Jie Tourism Group Co Ltd
SHE:000430
|
0.153x |
|
Cabaletta Bio Inc
NASDAQ:CABA
|
-0.247x |
|
Fujian Raynen Tech Co Ltd
SHG:603933
|
0.038x |
|
Probe Metals Inc
OTCQB:PROBF
|
-0.217x |
|
Shanghai Flyco Electrical Appliance Co Ltd
SHG:603868
|
0.085x |
|
Hextar Global Bhd
KLSE:5151
|
0.160x |
|
MediaAlpha Inc.
NYSE:MAX
|
-0.359x |
|
GSW Immobilien AG
HM:GIB
|
0.004x |
Annual Cash Flow Conversion Efficiency for Entrada Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Entrada Therapeutics Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $428.68 Million | $-41.56 Million | -0.097x | -116.81% |
| 2023-12-31 | $242.36 Million | $139.80 Million | 0.577x | +230.73% |
| 2022-12-31 | $212.55 Million | $-93.79 Million | -0.441x | -159.14% |
| 2021-12-31 | $298.72 Million | $-50.86 Million | -0.170x | -127.63% |
| 2020-12-31 | $-41.49 Million | $-25.57 Million | 0.616x | -11.46% |
| 2019-12-31 | $-15.52 Million | $-10.80 Million | 0.696x | -- |